Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Metavia Inc Is A Clinical-Stage Biotechnology Company Focused On Developing Novel Pharmaceuticals To Treat Cardiometabolic Diseases. It Has Two Programs Focused On The Treatment Of Metabolic Dysfunction-Associated Steatohepatitis (Mash) And Obesity. Vanoglipel (Da-1241) Is A Novel Gpr119 (Gpr119) Agonist With Development Optionality As A Standalone Or Combination Therapy For Both Mash And Type 2 Diabetes Mellitus (T2dm). Agonism Of Gpr119 In The Gut Promotes The Release Of Key Gut Peptides, Glucagon-Like Peptide-1 (Glp-1), Glucagon-Dependent Insulinotropic Polypeptide Receptor (Gip), And Peptide Yy.